English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Immune checkpoint inhibitors such as ipilimumab (anticytotoxic T-lymphocyte–associated antigen), pembrolizumab, and nivolumab (anti–programmed death receptor 1) represent some of the newest and most promising medications for the treatment of metastatic melanoma.1 As a class, immune checkpoint inhibitors interfere with tumoral suppression of T cells, resulting in a more robust immune response and subsequent benefit in the treatment of melanoma, non–small-cell lung cancer, and potentially other malignancies. Unfortunately, immune checkpoint inhibitors also interfere with suppression of autoimmunity, and several immune-related adverse events have been attributed to these medications.2, 3, 4 Patients receiving programmed death receptor 1 (PD-1) inhibitors have had morbilliform eruptions, vitiligo, pruritus, neutrophilic dermatosis, lichen planus, psoriasis, bullous erythema multiforme, Stevens-Johnson syndrome, and bullous pemphigoid.1, 2, 3, 4, 5, 6, 7, 8, 9, 10 Here we present a novel case of a pityriasis lichenoides chronica–like drug eruption developing during pembrolizumab therapy.

Pityriasis lichenoides chronica–like drug eruption developing during pembrolizumab treatment for metastatic melanoma